The present disclosure provides cell therapy production systems that can suitably be used in a patient bedside setting. Such systems allow for direct removal of a patient's blood, automated processing to produce a cell therapy, and then infusion back into the patient, without the need to remove the system from the patient's bedside. Also provided herein are systems for production of cell therapies in a bedside setting.

Disclosed is a multiple bag system for fractionating a fluid, including a fluid collecting bag with at least one outlet port; at least first and second sampling bags, each having at least one inlet port and at least one outlet port; and a mechanism for transferring fluid from the fluid collecting bag to the sampling bags. The fluid transfer mechanism includes an acoustic sorter. Also disclosed is a method for fractionating a fluid into fluid products.

A method for removing fat from salvaged blood includes transferring salvaged blood from a reservoir to a blood component separation device, and separating the blood into a plurality of blood components. The method may then transfer a volume of unwashed blood components from the blood component separation device back toward the reservoir, and re-centrifuge the blood components remaining within the blood component separation device. After re-centrifuging, the method transfers additional salvaged blood from the reservoir to the blood component separation device to refill the blood component separation device. The method may then wash the components within the bowl by introducing wash solution into the blood component separation device. The wash solution displaces a volume of fat from the blood component separation device and into a waste container. The method may then empty the washed blood components within the blood component separation device to a product container.

Devices and methods are provided herein for exchange between a first agent and a second agent. The device includes a first chamber having a first inlet and a first outlet with a first flow passageway extending between the first inlet and the first outlet for flowing a first agent through the first chamber. The device also includes a second chamber having a second inlet and a second outlet with a second flow passageway extending between the second inlet and the second outlet for flowing a second agent through the second chamber and a membrane positioned between the first flow passageway and the second flow passageway to allow exchange through the membrane of the first agent with the second agent. Methods of nitrosylating blood and methods of manufacturing the device are also provided.

A blood processing apparatus includes a measurement device having at least one chamber element extending along a longitudinal axis and including a circumferential wall extending about the longitudinal axis, a bottom wall and a top wall together defining a flow chamber. The blood processing apparatus further includes a holder for the measurement device, the holder including a base having a reception opening for receiving the measurement device and a closure element movably arranged on the base for locking the measurement device in an inserted position in the reception opening. An ultrasonic sensor of the holder is arranged on the base. The ultrasonic sensor, in the inserted position of the measurement device, faces the bottom wall of the at least one chamber element, wherein the bottom wall extends transversely with respect to the longitudinal axis.

The present invention is directed to a method for thawing a frozen biological sample including subjecting the frozen biological sample to a temperature ranging from 30 C. to 80 C. and simultaneously applying a negative pressure to the frozen biological sample. Further provided is a biological sample thawed according to the method of the invention.

This invention relates in general to the field of cell-therapy treatments and more particularly, but not by way of limitation, to systems and methods for administering personalized cell-therapy treatments intravenously. In various embodiments, the system may calculate an aspiration volume needed for centrifugation to achieve a concentrated target threshold dose of 210.sup.6 platelets/L for a particular cell therapy using various factors such as, for example, information about a patient and the efficiency of the concentration process.

Methods and compositions for the prevention or reduction of platelet transfusion associated complications are provided. The subject methods include modifying donor whole blood or platelets prior to transfusion to prevent or reduce alloimmune platelet refractoriness.

Provided is an adsorbent for removing histones from a liquid derived from a living-organism, including a water-insoluble carrier and a biocompatible polymer. The carrier has activated carbon, a polyester, a polysulfone, or a cationic functional group. Also provided is a device for purifying a liquid derived from a living-organism to remove histones from a liquid derived from a living-organism, which has a housing equipped with an inlet and an outlet for the liquid derived from the living-organism and the above-described adsorbent housed in the housing. The liquid derived from the living-organism is moved through the housing of device for purifying the liquid derived from the living-organism to remove histones from the liquid derived from the living-organism.

A platelet collection method includes a step of accommodating whole blood in a first chamber (44) and performing centrifugal separation, a step of transferring a buffy coat resulting from the centrifugal separation to a second chamber (50), and a step of performing centrifugal separation on the buffy coat. Subsequently, a step of transferring a platelet-containing component resulting from the centrifugal separation to a third chamber (52) and a step of performing centrifugal separation on the platelet-containing component are executed. Also performed in the collection method are a step of introducing a platelet additive solution into the third chamber (52) and replacing plasma resulting from the centrifugal separation and a step of collecting platelets remaining in the third chamber (52) along with the platelet additive solution.